Finance

Lists
002773:SHE
Chengdu Kanghong Pharma Grp Co Ltd
CN¥ 19.82
-1.29%
(-0.26) 1D
10-р сарын 15, 15:04:30 (GMT+8)  ·   CNY
All symbols
SymbolPriceChange% Change
Generating top insights for 002773...
Open
CN¥ 19.88
High
CN¥ 20.25
Low
CN¥ 19.72
Mkt. cap
18.61 тэрбум
Avg. vol.
7.27 сая
Volume
5.86 сая
Dividend
3.53%
Quarterly dividend
CN¥ 0.17
Ex-dividend date
2026 оны 6-р сарын 9
P/E ratio
18.35
52-wk high
CN¥ 36.10
52-wk low
CN¥ 18.62
EPS
CN¥ 1.08
Shares outstanding
921.33 сая
No. of employees
4 мян
Open
CN¥ 19.88
High
CN¥ 20.25
Low
CN¥ 19.72
Mkt. cap
18.61 тэрбум
Avg. vol.
7.27 сая
Volume
5.86 сая
Dividend
3.53%
Quarterly dividend
CN¥ 0.17
Ex-dividend date
2026 оны 6-р сарын 9
P/E ratio
18.35
52-wk high
CN¥ 36.10
52-wk low
CN¥ 18.62
EPS
CN¥ 1.08
Shares outstanding
921.33 сая
No. of employees
4 мян
News stories
From web sources and news partners
Profile
Chengdu Kanghong Pharmaceutical Group Co., Ltd. is a publicly traded pharmaceutical company based in the province of Sichuan, China. It was founded in 1996 and researches, develops, manufactures, and distributes medicines for ophthalmic, central nervous, digestive and endocrine systems. The company is listed on the Shenzhen stock exchange with a market capitalization at around $6 billion. As of May 2021, the company had 18 drugs on the market including Lumitin. Additional products include Songling xuemaikang capsules, Keluoxin capsules, Xinluona, Bolexin and Bosiqing, Yitaning, Shugan Jieyu, Danshu, and Yiqing. Kanghong also currently has 13 subsidiaries in China, Israel, and the United States. Wikipedia
About Chengdu Kanghong Pharma Grp Co Ltd
CEO-
Employees4.47 мян
Founded1996 оны 10-р сарын 3
Headquarters-
SectorPharmaceutical industry
Websitecnkh.com
Previous reportsAll values in CNY
Loading Previous Earnings...
Revenue
Net income
All values in CNY
2025 оны 9-р сар
2025 оны 12-р сар
2026 оны 3-р сар
2026 оны 6-р сар
Revenue
1.17 тэрбум
961.27 сая
1.05 тэрбум
1.13 тэрбум
Cost of goods sold
103.16 сая
116.91 сая
118.65 сая
132.03 сая
Cost of revenue
103.16 сая
116.91 сая
118.65 сая
132.03 сая
Research and development expenses
119.54 сая
198.94 сая
86.77 сая
138.57 сая
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
595.28 сая
521.75 сая
478.88 сая
554.55 сая
Operating expense
697.02 сая
764.40 сая
582.81 сая
717.78 сая
Total operating expenses
800.18 сая
881.31 сая
701.46 сая
849.80 сая
Operating income
370.02 сая
79.96 сая
345.02 сая
282.88 сая
Other non operating income
-19.53 сая
19.27 сая
-1.04 сая
-1.54 сая
EBT including unusual items
355.99 сая
147.66 сая
358.51 сая
301.88 сая
EBT excluding unusual items
364.66 сая
135.96 сая
356.39 сая
306.28 сая
Income tax expense
56.73 сая
23.28 сая
55.31 сая
50.13 сая
Effective tax rate
15.94%
15.77%
15.43%
16.61%
Other operating expenses
-17.83 сая
43.89 сая
16.62 сая
23.18 сая
Net income
303.21 сая
130.06 сая
307.48 сая
257.26 сая
Net profit margin
25.91%
13.53%
29.38%
22.71%
Earnings per share
-
-
-
-
Interest and investment income
14.20 сая
36.91 сая
12.63 сая
24.92 сая
Interest expense
-
-
-
-
Net interest expenses
14.20 сая
36.91 сая
12.63 сая
24.92 сая
Depreciation and amortization charges
-
-
-
-
EBITDA
427.31 сая
139.05 сая
404.11 сая
345.15 сая
Gain or loss from assets sale
3.47 мян
-9.78 мян
-
61.06 мян
AI content may include mistakes. Learn more
Google аппс